Trusted by the world’s leading institutions

clients clients clients clients clients clients clients clients clients clients clients
29-May-2024 9:00 AM EDT
Synthetic estrogen associated with increased anxiety-like behaviors in a rat model
Endocrine Society

The type of estrogen in hormonal birth control may influence anxiety-like behaviors, according to data presented by Abigail Hegwood, M.S., from the Prakapenka Lab at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

29-May-2024 9:00 AM EDT
Asian patients more likely to develop type 2 diabetes 1 year after prediabetes diagnosis compared to white and Black patients
Endocrine Society

One year after a prediabetes diagnosis, Asians were more likely to develop diabetes mellitus whereas Black patients were more likely to remain in prediabetes range, highlighting racial disparities in diabetes prevention, according to data presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

29-May-2024 9:00 AM EDT
Higher blood concentrations of testosterone are associated with reduced risk of developing type 2 diabetes in men under 65
Endocrine Society

Testosterone appears protective against developing type 2 diabetes in men who are overweight or obese and under age 65, but not in men over that age, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

29-May-2024 9:00 AM EDT
Race and social vulnerability impact glycemic control in people with diabetes
Endocrine Society

People of color and those who experience social vulnerability are more likely to experience worse glycemic control than their white counterparts, according to research presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

29-May-2024 9:00 AM EDT
GLP-1 has the power to change taste sensitivity in women with obesity
Endocrine Society

Semaglutide improved taste sensitivity, changed gene expression in the tongue that’s responsible for taste perception, and changed the brain’s response to sweet tastes, according to research presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

29-May-2024 9:00 AM EDT
Prediabetes raises Mexicans’ risk of dying prematurely of heart or kidney disease
Endocrine Society

Prediabetes increases the risk of dying before age 75, particularly due to heart disease, kidney disease and acute diabetic complications, according to a new study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

Released: 1-Jun-2024 9:00 AM EDT
Childhood sedentariness may cause premature liver damage in young adulthood
Endocrine Society

Children who are sedentary for more than six waking hours a day have a significantly increased risk of severe fatty liver disease and liver cirrhosis by young adulthood, a new study finds. The research findings will be presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass and published in Nature’s npj Gut and Liver.

29-May-2024 9:05 AM EDT
Childhood stress linked with earlier substance use in male and female teens
Endocrine Society

Stress during childhood is associated with earlier substance use in male and female adolescents, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. Traumatic events may increase substance use risk for males, while environmental stress and early puberty may increase the risk for females, the researchers found.

29-May-2024 9:00 AM EDT
Insurance often denies GLP-1 medications for teens with type 2 diabetes, obesity
Endocrine Society

Health insurance companies often deny coverage for new medications that treat children and teens with obesity and type 2 diabetes, meaning many patients who need treatment are unable to afford it, according to a study presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

Released: 1-Jun-2024 8:05 AM EDT
Clinical trials show promise in treating central nervous system lymphoma, breast cancer, and glioblastoma
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.


close
1.59003